We bring “miracles in medicine” to make a better future (mirai) in people's lives.
ABOUT USINNOVATIVE NEOBIOLOGICS
We use a simple, elegant technology called LassoGraft Technology® to extend the boundaries of biopharmaceuticals, creating new, innovative Neobiologics (multifunctional biopharmaceuticals) and bringing them to those who need them.
Portfolio
We build up a rich, varied portfolio by applying LassoGraft Technology® to a wide variety of modalities and therapeutic areas.
PORTFOLIO
Science
LassoGraft Technology®, by grafting target-specific cyclic peptides onto any proteins in the body, transforms them into biologically active proteins, creating new biopharmaceutical Neobiologics.
SCIENCE- Speed
- Robustness and reliability
- Plug & Play
- Multifunctionality
Partnership
In drug development, we value collaboration with pharmaceutical companies. The essence of collaboration is to combine our partners’ drug development expertise and experience with our LassoGraft Technology®, to create cutting-edge biopharmaceuticals rapidly and deliver them to patients worldwide who need them.
PARTNERSHIPNews
ALL NEWS-
2023.08.21We will have a booth at BioJapan, a partnering event (Location: Pacifico Yokohama, October 11 (Wed) - 13 (Fri), 2023, 10:00-17:00). We will be located at booth area, booth number: C-12, so please stop by if you are interested in our activities.
-
2023.07.01We have opened an official LinkdIn account for MiraBiologics, Inc. We will announce hot information about our company from time to time, so please follow us if you are interested.
-
2023.06.27June 26: Our founding director, Professor Hiroaki Suga at the University of Tokyo, attended the 2023 Wolf Prize for Chemistry award ceremony held on June 15 and accepted the award. We congratulate him on receiving the prestigious Wolf Prize.
-
2023.05.10May 10: We have renewed our website.
-
2023.02.09Feb 9: Our founding director, Prof. Hiroaki Suga at the University of Tokyo, has been awarded the prestigious 2023 Wolf Prize in Chemistry.
-
2022.12.05Feb 1 [Japanese Only] Prof. Junichi Takagi, Osaka University, and Prof. Hiroaki Suga, University of Tokyo, have contributed an article on LassoGraft Technology in "Jikken Igaku Zokan Vol. 40 No. 20, Antibody Medicine Expands Therapeutic Possibilities" published by Yodosha.